Efalizumab
- Generic Name
- Efalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 214745-43-4
- Unique Ingredient Identifier
- XX2MN88N5D
- Background
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a poten...
- Indication
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Associated Therapies
- -
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00312026
A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis
- Conditions
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2007-07-13
- Lead Sponsor
- Derm Research, PLLC
- Target Recruit Count
- 20
- Registration Number
- NCT00302445
- Locations
- ๐บ๐ธ
Dermatology Associates, PLLC, Seattle, Washington, United States
๐บ๐ธDerm Research, PLLC, Louisville, Kentucky, United States
A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 189
- Registration Number
- NCT00287118
- Locations
- ๐จ๐ญ
Medical Information Switzerland, Geneva, Switzerland
Efalizumab to Treat Uveitis
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 6
- Registration Number
- NCT00280826
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Islet Transplantation Using Abatacept
- Conditions
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT00276250
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 96
- Registration Number
- NCT00184366
- Locations
- ๐ณ๐ด
Dep of dermatology, St Olavs Hospital, Trondheim, Norway
Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa
- Conditions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 5
- Registration Number
- NCT00134134
- Locations
- ๐บ๐ธ
New York University School of Medicine, Dept of Dermatology, New York, New York, United States
Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 4
- Registration Number
- NCT00133107
- Locations
- ๐บ๐ธ
Washington University, St. Louis, Missouri, United States
Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2005-06-21
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 31
- Registration Number
- NCT00115076
- Locations
- ๐บ๐ธ
The Rockefeller University, New York, New York, United States
๐บ๐ธRockefeller University, New York, New York, United States
Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
- Conditions
- First Posted Date
- 2003-01-16
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- XOMA (US) LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00051662
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.